Discontinuation of anti‐PD ‐1 monotherapy in advanced melanoma—Outcomes of daily clinical practice-Reference-Cited by-同舟云学术

Discontinuation of anti‐PD ‐1 monotherapy in advanced melanoma—Outcomes of daily clinical practice

Published:2021-10-02 Issue:2 Volume:150 Page:317-326
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Zeijl Michiel C. T.¹²^ORCID,Eertwegh Alfons J. M.³,Wouters Michel W. J. M.¹⁴⁵,Wreede Liesbeth C.⁵,Aarts Maureen J. B.⁶,Berkmortel Franchette W. P. J.⁷,Groot Jan‐Willem B.⁸,Hospers Geke A. P.⁹,Kapiteijn Ellen²,Piersma Djura¹⁰,Rijn Rozemarijn S.¹¹,Suijkerbuijk Karijn P. M.¹²,Tije Albert J.¹³,Veldt Astrid A. M.¹⁴,Vreugdenhil Gerard¹⁵,Hoeven Jacobus J. M.¹⁶,Haanen John B. A. G.¹⁷

Affiliation:

1. Scientific Department Dutch Institute for Clinical Auditing Leiden The Netherlands

2. Department of Medical Oncology Leiden University Medical Center Leiden The Netherlands

3. Department of Medical Oncology Amsterdam UMC – Location VUmc Amsterdam The Netherlands

4. Department of Surgical Oncology Netherlands Cancer Institute Amsterdam The Netherlands

5. Department of Biomedical Data Sciences Leiden University Medical Center Leiden The Netherlands

6. Department of Medical Oncology Maastricht University Medical Center+ Maastricht The Netherlands

7. Department of Medical Oncology Zuyderland Medical Center Sittard‐Geleen The Netherlands

8. Department of Medical Oncology Isala Oncology Center Zwolle The Netherlands

9. Department of Medical Oncology University Medical Center Groningen Groningen The Netherlands

10. Department of Internal Medicine Medical Spectrum Twente Enschede The Netherlands

11. Department of Internal Medicine Medical Center Leeuwarden Leeuwarden The Netherlands

12. Department of Medical Oncology University Medical Center Utrecht Utrecht The Netherlands

13. Department of Internal Medicine Amphia Hospital Breda The Netherlands

14. Department of Medical Oncology Erasmus Medical Center Rotterdam The Netherlands

15. Department of Internal Medicine Maxima Medical Center Eindhoven The Netherlands

16. Department of Medical Oncology Radboudumc Nijmegen The Netherlands

17. Divisions of Medical Oncology and Molecular Oncology and Immunology Netherlands Cancer Institute Amsterdam The Netherlands

Funder

Les Laboratories Pierre Fabre

Novartis

Bristol-Myers Squibb

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.33800

Reference22 articles.

1. Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy

2. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

3. Treatment duration with immune-based therapies in Cancer: an enigma

4. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors

5. Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes of patients with advanced solid tumors who discontinued immune-checkpoint inhibitors: a systematic review and meta-analysis;eClinicalMedicine;2024-07

2. Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab – study protocol;BMC Cancer;2024-05-23

3. Long‐term survival with systemic therapy in the last decade: Can melanoma be cured?;The Journal of Dermatology;2024-02-15

4. Extended duration of treatment using reduced-frequency dosing of anti-PD-1 therapy in patients with advanced melanoma and Merkel cell carcinoma;Cancer Immunology, Immunotherapy;2023-09-21

5. Efficacy of Immune Checkpoint Inhibitor (ICI) Rechallenge in Advanced Melanoma Patients’ Responders to a First Course of ICI: A Multicenter National Retrospective Study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC);Cancers;2023-07-10